Center For Scientific Review; Notice of Closed Meeting., 36936 [2016-13498]
Download as PDF
<![CDATA[
36936
Federal Register / Vol. 81, No. 110 / Wednesday, June 8, 2016 / Notices
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Rass M. Shayiq, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182,
MSC 7818, Bethesda, MD 20892, (301) 435–
2359, shayiqr@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 2, 2016.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–13497 Filed 6–7–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
Center For Scientific Review; Notice of
Closed Meeting.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Oligodendrocyte Differentiation and
Myelination.
Date: June 9, 2016.
Time: 12:30 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Carole L Jelsema, Ph.D.,
Chief and Scientific Review Officer, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4176,
MSC 7850, Bethesda, MD 20892, (301) 435–
1248, jelsemac@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
Jkt 238001
National Institutes of Health,
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
ADDRESSES: Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: Therapeutic
antibody-drug conjugates targeting
CD56-positive tumors.
Description of Technology: CD56, also
known as neural cell adhesion molecule
(NCAM), is a glycoprotein that plays an
important role in normal physiological
functions. It is expressed in low levels
in normal cells such as neurons, glia,
skeletal muscle and natural killer cells
SUMMARY:
National Institutes of Health
mstockstill on DSK3G9T082PROD with NOTICES
[FR Doc. 2016–13498 Filed 6–7–16; 8:45 am]
ACTION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
17:30 Jun 07, 2016
Dated: June 2, 2016.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
HHS.
BILLING CODE 4140–01–P
VerDate Sep<11>2014
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS).
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
but is highly expressed on a variety of
cancerous cells including
neuroblastoma, small-cell lung cancer,
and multiple myeloma. In
neuroblastoma, patients undergo a very
aggressive treatment regimen that still
results in a high mortality rate. Many
neuroblastomas have increased
expression of CD56 which represents a
possible therapeutic target for these
aggressive and hard to treat cancers.
Researchers at the National Cancer
Institute’s Cancer and Inflammation
Program, in collaboration with the
Children’s Hospital of Philadelphia
(CHOP), have developed antibody-drug
conjugates (ADC) that incorporate one of
two novel human CD56 antibodies,
known as m900 and m906, in
combination with a known cytotoxic
drug, pyrrolobenzodiazepine (PBD).
Other PBD–ADCs have demonstrated
the ability to overcome resistance in
some multi-drug resistant cancers which
could present additional benefits for the
ADCs of the current invention. The
m900 and m906 ADCs have been shown
to induce cell death and CD56 down
regulation in vitro in four different
CD56-positive neuroblastoma cell lines.
Preliminary studies in animals have also
shown promising results, and additional
in vivo work is ongoing.
Potential Commercial Applications:
—Therapeutic for the treatment of
neuroblastoma
—Therapeutic for the treatment of other
CD56-positive cancers including
small cell lung cancer, multiple
myeloma, pancreatic cancer, ovarian
cancer, acute myeloid leukemia, NK–
T lymphoma, and neuroendocrine
cancer
Value Proposition:
—Fully human antibodies (m900 or
m906) targeting CD56 may offer
improved properties over the
humanized antibody IMGN901
Development Stage: Pre-clinical (in
vivo validation).
Inventor(s): Dimiter S. Dimitrov (NCI),
Yang Feng (NCI), Zhongyu Zhu (NCI),
John M. Maris (Children’s Hospital of
Philadelphia).
Intellectual Property: HHS Reference
No. E–221–2015/0–US–01. US
Provisional Application No. 62/199,707,
filed July 31, 2015 entitled
‘‘ANTIBODY–DRUG CONJUGATES
FOR TARGETING CD56–POSITIVE
TUMORS’’.
Publications: Feng, Y, et al.
Differential killing of CD56-expressing
cells by drug-conjugated human
antibodies targeting membrane-distal
and membrane-proximal nonoverlapping epitopes. mAbs, 2016;
E:\FR\FM\08JNN1.SGM
08JNN1
]]>Agencies
[Federal Register Volume 81, Number 110 (Wednesday, June 8, 2016)]
[Notices]
[Page 36936]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-13498]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of Closed Meeting.
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Oligodendrocyte Differentiation and
Myelination.
Date: June 9, 2016.
Time: 12:30 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Carole L Jelsema, Ph.D., Chief and Scientific
Review Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4176, MSC 7850, Bethesda, MD
20892, (301) 435-1248, jelsemac@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS).
Dated: June 2, 2016.
Carolyn Baum,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-13498 Filed 6-7-16; 8:45 am]
BILLING CODE 4140-01-P
